Is hypercoagulation a predictor influencing the efficiency of immunotherapy for metastatic renal cancer?

Cover Page

Cite item

Full Text

Abstract

In experimental systems, interference with coagulation can affect tumor biology. Tumor-mediated activation of the hemostatic system has been implicated in both the formation of tumor stroma and the promotion of hematogenous metastasis. We emphasize that hypercoagulation is a frequent symptom in metastatic renal cell carcinoma (MRCC) patients and clinically correlates with progression of the disease. It has been suggested that hypercoagulation is a possible negative predictor for a response to immunotherapy in MRCC patients.

About the authors

I. V. Timofeyev

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences I.M. Sechenov Moscow Medical Academy

Author for correspondence.
Russian Federation

A. V. Madzhuga

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences I.M. Sechenov Moscow Medical Academy

Russian Federation

L. V. Demidov

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences I.M. Sechenov Moscow Medical Academy

Russian Federation

O. V. Somonova

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences I.M. Sechenov Moscow Medical Academy

Russian Federation

G. Yu. Kharkevich

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences I.M. Sechenov Moscow Medical Academy

Russian Federation

A. L. Yelizarova

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences I.M. Sechenov Moscow Medical Academy

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.